Is there a role for steroid therapy in severe dengue with central nervous system involvement?

No Routine Steroid Use in Severe Dengue with CNS Involvement

There is insufficient evidence to support routine corticosteroid use in severe dengue with CNS involvement, and the available data suggest no clear benefit with potential harm. The decision to use steroids should be reserved for specific immune-mediated complications rather than routine CNS involvement.

Evidence Against Routine Steroid Use

The most comprehensive evidence comes from a Cochrane systematic review 1 that evaluated corticosteroids in dengue across multiple clinical scenarios. This review found:

• No mortality benefit in dengue-related shock (4 trials, 284 participants, very low quality evidence)
• No prevention of severe complications when given early in dengue infection (4 trials, 664 participants, low quality evidence)
• No reduction in shock development, severe bleeding, or ICU admissions
• The authors concluded there is insufficient evidence to support corticosteroid use outside of clinical trials

This represents the highest-quality systematic evidence available and should guide clinical decision-making 1.

When Steroids May Be Considered

Despite the lack of routine benefit, steroids have been used in specific dengue-related neurological syndromes:

Immune-Mediated Complications

• Acute transverse myelitis or longitudinally extensive transverse myelitis: Intravenous corticosteroids were administered in 62% of cases, with complete or near-complete recovery in 46% 2
• Dengue-associated hemophagocytic lymphohistiocytosis (HLH): Short courses (3-4 days) of high-dose dexamethasone (10 mg/m²) showed favorable outcomes when HLH criteria are met 3
• Isolated cranial nerve palsies: Often steroid-responsive, though these are uncommon 4

Diagnostic Criteria for HLH

Consider HLH in severe dengue with:

• Prolonged or recurrent fever >7 days
• Anemia without intravascular hemolysis or massive bleeding
• Requires fulfilling ≥5 of 8 HLH-2004 criteria 3

Clinical Algorithm

For dengue encephalitis/encephalopathy without specific immune-mediated features:

• Do not use routine corticosteroids 1
• Focus on supportive care, fluid management, and monitoring for complications
• Screen for alternative diagnoses

For suspected immune-mediated complications (ADEM, transverse myelitis, HLH):

• Confirm diagnosis with appropriate imaging and laboratory criteria
• Consider high-dose IV methylprednisolone (1 g daily for 3-5 days) or dexamethasone (10 mg/m² for 3-4 days) 3, 2
• Monitor closely for hemorrhagic complications given dengue's coagulopathy risk

For isolated cranial neuropathies:

• Rule out other causes first
• Consider steroid trial if immune-mediated mechanism suspected 4

Critical Caveats

1. Hemorrhagic risk: Dengue causes thrombocytopenia and coagulopathy; steroids may theoretically worsen bleeding risk, though this hasn't been definitively proven 1

2. Viral replication concerns: While theoretical concerns exist that steroids could facilitate viral replication, this hasn't been demonstrated clinically in the limited available data 5

3. Quality of evidence: The evidence base is weak (very low to low quality), with most steroid trials in dengue being >20 years old with methodological limitations 1

4. Case reports vs. systematic evidence: Individual case reports 6 describe steroid success, but the systematic review evidence 1 does not support routine use—prioritize the systematic evidence

5. Distinguish encephalitis from encephalopathy: Direct viral invasion (encephalitis) versus metabolic/vascular complications (encephalopathy) may respond differently, though evidence doesn't clearly support steroids for either 7, 4

The evidence strongly suggests avoiding routine corticosteroids in dengue CNS involvement unless specific immune-mediated complications are documented.